Berinert denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BlueCross BlueShield May Deny Berinert as Non-Formulary

Berinert is a plasma-derived C1 esterase inhibitor (C1-INH) used for acute hereditary angioedema (HAE) attacks. When BCBS's formulary does not include Berinert — or places it on a tier that effectively makes it inaccessible — the plan will deny coverage as "non-formulary." This most often occurs when the formulary includes a different HAE acute-treatment agent as the preferred alternative. Non-formulary denials are not final: federal and state law provide a formulary exception process, and the medical-necessity exception pathway is specifically designed for situations where the formulary alternative is clinically inappropriate for a specific patient.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you have the right to request a formulary exception and, if denied, to appeal that denial through the full internal and external review process. The external-review window is generally within four months of the final adverse determination. Because HAE attacks can be life-threatening, expedited review (72-hour decision) is available and appropriate when there is clinical urgency. Many states have additional formulary exception protections — check whether your state's law strengthens these rights for your plan type.

## The Appeal Process

1. Request the BCBS formulary exception form and the coverage policy for Berinert and for the preferred formulary HAE agent. 2. File a formulary exception request with clinical documentation supporting why the preferred agent is not appropriate for this patient. 3. If the exception is denied, file a Level 1 internal appeal. 4. If upheld, escalate to Level 2 and then external IRO review. 5. For urgent situations, submit simultaneously as an expedited review.

## Documentation to Gather

• HAE diagnosis confirmation: Genetic or laboratory confirmation of hereditary angioedema type, confirming the patient requires an acute C1-INH product.
• Formulary alternative trial or contraindication: If the preferred formulary agent was tried and failed, provide records with dates and documented outcomes. If it was not tried because of a documented medical reason (contraindication, intolerance, or clinical unsuitability), provide the prescriber's explanation.
• Clinical rationale for Berinert specifically: A letter from the treating HAE specialist explaining why Berinert — rather than the formulary alternative — is medically necessary for this patient, citing any patient-specific factors (prior response, home self-administration capability, product familiarity, or clinical characteristic) that make Berinert the appropriate choice.
• Attack severity records: Documentation of attack frequency and severity establishing clinical urgency and the need for a reliable acute-treatment option.
• Prescriber medical-necessity letter: A comprehensive letter addressing the formulary exception criteria, citing the applicable HAEA guideline, and confirming that the formulary alternative is not an adequate substitute for this patient.

## Criteria-Mapping Structure

Obtain the BCBS formulary exception criteria and the coverage policy for the preferred HAE agent, then map:

| Formulary Exception Criterion | Satisfying Documentation | |---|---| | Confirmed diagnosis requiring this drug class | Lab/genetic confirmation + specialist note | | Formulary alternative clinically inappropriate | Trial records, intolerance note, or clinical-rationale letter | | Berinert medically necessary for this patient | HAE specialist letter with patient-specific rationale | | Clinical urgency (if expedited) | Attack history + specialist attestation of urgency |

Formulary exception decisions turn almost entirely on the quality of the prescriber letter — a detailed, patient-specific letter from an HAE specialist carries significantly more weight than a generic medical-necessity statement.